ICU Intervention Doesn't Impact Surrogate Psychological Burden

Share this content:
ICU Intervention Doesn't Impact Surrogate Psychological Burden
ICU Intervention Doesn't Impact Surrogate Psychological Burden

WEDNESDAY, May 23, 2018 (HealthDay News) -- A family-support intervention delivered by the interprofessional intensive care unit (ICU) team does not significantly impact surrogates' burden of psychological symptoms, according to a study published online May 23 in the New England Journal of Medicine to coincide with the American Thoracic Society's 2018 International Conference, held from May 18 to 23 in San Diego.

Douglas B. White, M.D., from the University of Pittsburgh School of Medicine, and colleagues conducted a trial involving patients with a high risk of death and their surrogate decision makers in five ICUs to compare a multicomponent family-support intervention delivered by the interprofessional ICU team with usual care. A total of 1,420 patients were enrolled in the trial.

The researchers found that the intervention and control groups did not differ significantly in terms of the surrogates' mean Hospital Anxiety and Depression Scale (HADS) score at six months (11.7 versus 12.0) or in the mean Impact of Event Scale score (21.2 versus 20.3). Compared with the control group, the intervention group had a significantly better surrogate mean Quality of Communication scale score (69.1 versus 62.7), and mean modified Patient Perception of Patient Centeredness scale score (1.7 versus 1.8).

"Our data are not directive, but they suggest that equipoise is present and that a large replication trial may be conducted in multiple geographic regions to establish the generalizability of the findings," the authors write.

One author disclosed financial ties to Eli Lilly.

Abstract/Full Text
Editorial
More Information

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Trending Activities

All Professions

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

FDA Permits Marketing of Brain Stimulation Device for OCD

FDA Permits Marketing of Brain Stimulation Device for ...

FDA previously approved transcranial magnetic stimulation for major depression, certain migraines

Comments Open on End of NIH Review for Gene Therapy Studies

Comments Open on End of NIH Review for ...

NIH oversight panel no longer plans to review all applications for gene therapy experiments

U.S. Measles Outbreak Hits 107 Cases in 21 States, D.C.

U.S. Measles Outbreak Hits 107 Cases in 21 ...

Outbreak on track to exceed last year's; most of the people who got measles weren't vaccinated

is free, fast, and customized just for you!




Already a member?

Sign In Now »